GHRP-2

Growth Hormone Secretagogues

aka GHRP2 · Growth Hormone Releasing Peptide 2 · Pralmorelin

Compare

Formula

MW (Da)

Half-life

~15–60 min

Saves

Overview

GHRP-2 is a synthetic growth hormone secretagogue and ghrelin receptor agonist. The retrieved literature treats it primarily as a tool for studying GH secretion, appetite regulation, and growth physiology rather than as an established therapeutic drug.

Mechanism

Human and mechanistic sources identify GHRP-2 as a synthetic agonist at the GH secretagogue receptor (GHSR-1a), with downstream increases in GH secretion and food intake. In healthy humans and obesity studies, its orexigenic profile resembles ghrelin itself. In vitro and animal work also supports direct somatotroph effects, though not all actions are fully GHRH-independent.

Reported benefits

0

Vendors

—

no vendors yet

Lowest price

—

Increased food intake in healthy lean men

Subcutaneous infusion of 1 μg/kg/h for 270 minutes increased food intake by about 35% in healthy lean men — a magnitude comparable to ghrelin.

[ghrp2-laferrere-2005]

clinical

Appetite ratings and GH increased in obesity

In obese subjects, higher-dose GHRP-2 increased appetite ratings and GH levels.

[ghrp2-laferrere-2005]

clinical

Transient appetite increase without sustained weight gain (pediatric long-term)

A pediatric long-term study using 900 μg/kg twice daily produced a transient appetite increase during the first months of treatment but not a sustained rise in body weight — underscoring the gap between acute orexigenic signaling and durable benefit.

[ghrp2-laferrere-2005]

clinical

Reported side effects

No obvious side effects in extended intranasal study
clinical
A long-term intranasal study reported no obvious side effects after extended use, but this is not equivalent to a modern phase 1 safety dataset.
Modern phase-1-grade safety dataset not available
anecdotal
Adverse-event incidence remains incompletely characterized in the accessible sources; physiological endocrine effects dominate the existing literature.

Dosing notes

Human experimental regimens include SC infusion at 1 μg/kg/h for 270 minutes in appetite studies, and 900 μg/kg twice daily in a long-term pediatric study. These are study protocols, not validated standard-of-care dosing; formal safety margins are not defined in the retrieved literature.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Specific peer-reviewed stability data were not retrieved. Primary studies rarely detail storage. Supplier guidance for synthetic research peptides typically advises cold, dry, light-protected storage of lyophilized material with frozen long-term storage preferred.

Vendors carrying GHRP-2

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about GHRP-2.

No questions yet. Be the first to ask.

References

[ghrp2-laferrere-2005]
GHRP-2 increases food intake in healthy men
Laferrère B et al. · 2005 · PubMed
Source
[ghrp2-intranasal-longterm]
Long-term intranasal GHRP-2 study
Authors per PubMed entry · PubMed
Source

Increased food intake in healthy lean men

Appetite ratings and GH increased in obesity

Transient appetite increase without sustained weight gain (pediatric long-term)

No obvious side effects in extended intranasal study

Modern phase-1-grade safety dataset not available

Discussion